MOTS-c: What People Actually Pay and What the Evidence Shows

HealthRX.com

No approved MOTS-c product means no standard price

Print or save as PDF

Key numbers

  • 5 mgDose of the 5 mg and 10 mg injections nominated to FDA; no approved dose existsSource: fda.gov, as cited Nov 7, 2026
  • 20%Mice on a high-fat diet: lower body weight after 8 weeks at 0.5 mg/kg/daySource: fda.gov, as cited Nov 7, 2026
  • 15 mg/kgMice in a late-life study: 15 mg/kg three times weekly lengthened median lifespanSource: pubmed.ncbi.nlm.nih.gov, as cited Nov 7, 2026
  • 30 healthy adultsAdults in an exercise trial; none were given MOTS-c, only the body's own levels were measuredSource: pubmed.ncbi.nlm.nih.gov, as cited Nov 7, 2026
  • Approval status / Not FDA-approved; not a component of any approved drug [1]
  • Human studies / FDA found none in which MOTS-c was given to a person [1]
  • Bulks lists / Not on FDA's pharmacy or outsourcing-facility lists; category 1 does not cover it [3][4][5]
  • Forms marketed / Nominated to FDA as 5 mg and 10 mg subcutaneous injections; also offered in an IV cocktail by a wellness clinic [1]
  • HHS policy / Draft October 2026 notice covering MOTS-c acetate injection; not an approval [6][7]
  • Sport / Prohibited at all times by WADA under S4.4.1 [8][9]

Why there is no standard price to compare

MOTS-c is marketed on websites alone and in combinations, including an IV cocktail offered by a wellness clinic, for metabolism, weight loss, glucose control, performance and anti-aging [1]. No outsourcing facility reported compounding it from January 2017 to December 2025, so FDA's data offer no outsourcing-facility benchmark [1]. With no approved product, no approved dose and no human dosing study, there is no standard amount or course against which a monthly cost could be compared [1].

Questions worth asking

Choose the questions you want to keep

What the evidence shows

All of the pharmacology comes from animal and laboratory work. In mice, injected MOTS-c reduced weight gain on a high-fat diet (about 20% lower body weight after 8 weeks at 0.5 mg/kg/day given intraperitoneally) and improved insulin sensitivity and exercise performance [1]. In one study, a late-life schedule of 15 mg/kg three times weekly from 23.5 months of age lengthened median lifespan from 912 to 970 days [1][10]. FDA says the molecular targets are unknown and no dose-response relationships were assessed [1].

In people, the measurements were of the body's own MOTS-c. A 2021 randomized trial (von Walden et al.) assigned 30 healthy adults to endurance exercise (n=10), resistance exercise (n=10) or control (n=10); MOTS-c showed only a trend to increase after endurance exercise, and nobody received MOTS-c [11]. In the 2021 Nature Communications study (Reynolds et al.), exercise raised endogenous MOTS-c in muscle and blood; people were not given MOTS-c [10]. An in-vitro study FDA cited found MOTS-c breaks down quickly in human blood, raising the question whether injecting it can produce active levels [1].

Is there a dose?

There is no approved dose and no human dosing study [1]. The products nominated to FDA were 5 mg and 10 mg subcutaneous injections [1]. Rodent doses of 0.5 to 15 mg/kg cannot be converted into human doses, and FDA found no pharmacokinetic data in humans or live animals [1].

Where MOTS-c stands

MOTS-c is not on FDA's pharmacy bulks list or its list for outsourcing facilities, and FDA's category 1 policy does not cover it [3][4][5]. FDA staff proposed in July 2026 that neither the free base nor the acetate be added to the pharmacy bulks list, citing no human safety or effectiveness data and no animal toxicity studies [1]. The Pharmacy Compounding Advisory Committee voted on July 23, 2026 in favor of adding it, against staff's recommendation. That vote is advice only, is not binding, and did not put MOTS-c on any list [12][6].

HHS's draft enforcement-discretion policy, filed October 28, 2026, names MOTS-c among six peptides and covers the acetate form given by subcutaneous or intramuscular injection. It says HHS does not intend to take enforcement action against a state-licensed pharmacy, federal facility or licensed physician compounding with it if the policy's conditions are met, such as a single active ingredient, a patient-specific prescription and an FDA-registered manufacturer with a certificate of analysis [6][7]. The notice says it establishes no rights and is not binding, and HHS may revisit it [6]. Compounded drugs are not FDA-approved: FDA does not review their safety, effectiveness or quality before marketing [6].

WADA names MOTS-c in S4.4.1 among AMPK activators, prohibited at all times, on both the 2026 and 2027 Lists [8][9].

Is it safe?

Human safety is unknown. FDA's adverse-event searches through March 9, 2025 retrieved no MOTS-c reports, and FDA found no human exposure data by any route and no animal toxicity studies [1]. Its stated concern for injection is immunogenicity, an immune reaction, from aggregation and peptide-related impurities, and no immunogenicity data exist [1]. That MOTS-c is made naturally in the body does not establish that the injected synthetic peptide is safe [1].

Check what you know

Think you have it? Try 4 quick questions and see what the article says.

1. In the mouse study, what dose was given and for how long?

Question 1 of 4

Score: 0 right, 0 of 4 answered

How much does MOTS-c cost?
No approved product, approved dose or standard course exists to set a price benchmark, and no outsourcing facility reported compounding it from January 2017 to December 2025 [1].
Does MOTS-c work in humans?
FDA found no published study in which it was given to a human [1]. The weight, insulin and lifespan effects come from mice [1][2].
Where does MOTS-c stand legally?
It is not on FDA's pharmacy or outsourcing-facility bulks lists, and FDA's category 1 policy does not cover it [3][4][5]. A draft October 2026 HHS policy says it does not intend enforcement action against certain pharmacies and physicians compounding MOTS-c acetate injection if conditions are met; the notice is not binding [6].
Is MOTS-c banned in sport?
Yes. WADA names MOTS-c in S4.4.1 among AMPK activators, prohibited at all times, on both the 2026 and 2027 Lists [8][9].
Show all 12 referencesHide references
  1. U.S. Food and Drug Administration.
  2. Lee C, Zeng J, Drew BG, Sallam T, Martin-Montalvo A, Wan J, et al. The mitochondrial-derived peptide MOTS-c promotes metabolic homeostasis and reduces obesity and insulin resistance. Cell Metab. 2015;21(3):443-54.
  3. U.S. Food and Drug Administration.
  4. U.S. Food and Drug Administration.
  5. Bulk Drug Substances Used in Compounding of the FD&C Act | FDA.
  6. Official web page.
  7. Official web page.
  8. World Anti-Doping Agency.
  9. World Anti-Doping Agency.
  10. Reynolds JC, Lai RW, Woodhead JST, Joly JH, Mitchell CJ, Cameron-Smith D, et al. MOTS-c is an exercise-induced mitochondrial-encoded regulator of age-dependent physical decline and muscle homeostasis. Nat Commun. 2021;12(1):470.
  11. von Walden F, Fernandez-Gonzalo R, Norrbom J, Emanuelsson EB, Figueiredo VC, Gidlund EK, et al. Acute endurance exercise stimulates circulating levels of mitochondrial-derived peptides in humans. J Appl Physiol (1985). 2021;131(3):1035-1042.
  12. U.S. Food and Drug Administration.
Evidence overview for MOTS-c: What People Actually Pay and What the Evidence Shows